Study to assess the effect of surovatamig in participants with antibody-mediated kidney disease
Research type
Research Study
Full title
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults With Antibody-mediated Kidney Disease
IRAS ID
1013899
Contact name
Ming-Yuan Tseng
Contact email
Sponsor organisation
AstraZeneca AB
ISRCTN Number
N/A
Clinicaltrials.gov Identifier
N/A
Research summary
This is a Phase II open-label study to assess the safety, tolerability, Pharmacokinetics, and efficacy of surovatamig in adult participants with pMN, who are positive for anti-PLA2R antibodies and have heavy and persistent proteinuria with a high risk of progressing to end stage kidney disease. The study will be conducted across approximately 30 to 40 study sites in approximately 10 countries. The study consists of 2 parts (Part A Multiple ascending with sentinel dosing and Part B Multiple ascending doses), with each consisting of 3 periods (ie, screening period, treatment period, and follow-up period; up to 26 months in total).
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
26/NW/0092
Date of REC Opinion
1 May 2026
REC opinion
Further Information Favourable Opinion